Answers are grounded in this paper and cite their sources.
Targeted reduction of hepatic antithrombin (AT) via siRNA offers a promising strategy to enhance thrombin (TMB) generation in bleeding disorders, though efficient hepatocyte delivery remains challenging. This study developed and evaluated a targeted lipid nanoparticle (LNP) formulation incorporating a novel morpholine-based ionizable lipid (MIL) and a lactobionic-octadecylamine conjugate (LBN) for hepatocyte-specific delivery of AT-siRNA (siAT). Following synthesis of MIL and LBN, siAT-loaded LNP (siAT LNP LBN) were prepared using microfluidics and characterized for size, morphology, zeta potential, polydispersity index, and encapsulation efficiency (EE). Functional assays on HepG2 cells assessed cellular uptake, protein knockdown, and AT activity. The optimized formulation exhibited uniform particles (124 nm, PDI 0.125, zeta potential − 8.9 mV) and high EE (90%). Cytotoxicity assays confirmed safety up to 65 pmol siRNA. LBN-decorated LNP significantly enhanced hepatocyte uptake compared to non-targeted LNP and naked siRNA. Optimal AT mRNA suppression occurred at ~ 65 pmol siRNA and 16 h, with protein knockdown confirmed at 48 h. Functionally, siAT LNP LBN reduced AT activity to 48.1 ± 5.5%, substantially outperforming non-targeted LNP (64.1%) and naked siRNA (86.6%). The developed siAT-LNP-LBN platform demonstrated efficient hepatocyte uptake, robust AT knockdown, and low cytotoxicity in vitro, providing preliminary evidence for its potential as a hepatocyte-targeted siRNA delivery platform. Further in vivo studies are warranted to evaluate its biodistribution, liver-targeting efficiency, pharmacodynamic effects, therapeutic efficacy, and biosafety.
No takes yet. Share an insight, caveat, or question.
Zangi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: